Aktis Oncology, Inc. (AKTS)

Aktis Oncology Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2024	Dec 31, 2023
Net Income	-60.65	-43.98	-28.64
Depreciation & Amortization	-3.52	-2.51	-2.03
Share-Based Compensation	-	2.26	1.48
Other Operating Activities	2.48	58.99	-0.82
Operating Cash Flow	-61.69	14.76	-30
Capital Expenditures	-7.66	-2.86	-3.76
Change in Investments	-	-187.54	-65.12
Other Investing Activities	27.2	-	0.06
Investing Cash Flow	19.54	-190.4	-68.83
Share Issuance / Repurchase	-	185.18	-
Other Financing Activities	-2.24	-1.9	-
Financing Cash Flow	-2.24	183.28	-
Net Cash Flow	-44.39	7.65	-98.83
Free Cash Flow	-69.34	11.9	-33.77
Free Cash Flow Margin	-1247.19%	800.27%	-

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).